Literature DB >> 23067527

The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker.

P Ozcan Kara1, T Kara, B Kaya, G Kara Gedik, O Sari.   

Abstract

OBJECTIVES: This retrospective study was designed to assess the value of positron emission tomography/computed tomography imaging (PET/CT) in the post-treatment evaluation of the patients with endometrial carcinoma and to compare PET/CT scan with conventional imaging (CI) including computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) and CA 125 with both 20U/ml and 35U/ml cut-off values.
MATERIALS AND METHODS: A total of 31 patients who were treated for histopathologically proven endometrial adenocarcinoma, underwent PET/CT examination for restaging and suspected recurrence. Thirty five PET/CT studies were performed in 31 patients. Lesion status was determined on the basis of clinical follow-up including radiological imaging (follow-up CT scan) at least 6 months and response to therapy.
RESULTS: Of the 35 PET/CT studies, 13 (37%) studies were positive, whereas 22 (63%) of them were negative. On study-based analysis the overall sensitivity, specificity, accuracy for PET/CT imaging were 100%, 96% and 97%, respectively. The corresponding information for CI were 46%, 87% and 74%, for CA 125 (cut off=20U/ml) measurement were 45%, 88% and 74%, and for CA 125 (cut off=35U/ml) measurement were 27%, 100% and 78%, respectively. On lesion-based analysis, PET/CT revealed only one false positive case. In none of 21 patients with negative 22 PET/CT studies, no subsequent clinical or radiological recurrences were observed with a follow-up of at least 6 months.
CONCLUSION: FDG-PET/CT is found more useful modality than CI and CA 125 in the evaluation of post-treatment endometrial carcinoma patients, for suspected recurrence.
Copyright © 2011 Elsevier España, S.L. and SEMNIM. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23067527     DOI: 10.1016/j.remn.2011.06.001

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  2 in total

1.  Imaging in endometrial carcinoma.

Authors:  Silvana C Faria; Tara Sagebiel; Aparna Balachandran; Catherine Devine; Chandana Lal; Priya R Bhosale
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

Review 2.  Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature.

Authors:  Alessandra Musto; Gaia Grassetto; Maria Cristina Marzola; Sotirios Chondrogiannis; Anna Margherita Maffione; Lucia Rampin; David Fuster; Francesco Giammarile; Patrick M Colletti; Domenico Rubello
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.